FR2421174A1 - Nouveaux derives de carbostyrile, leur procede de preparation et leurs applications en therapeutique - Google Patents

Nouveaux derives de carbostyrile, leur procede de preparation et leurs applications en therapeutique

Info

Publication number
FR2421174A1
FR2421174A1 FR7907863A FR7907863A FR2421174A1 FR 2421174 A1 FR2421174 A1 FR 2421174A1 FR 7907863 A FR7907863 A FR 7907863A FR 7907863 A FR7907863 A FR 7907863A FR 2421174 A1 FR2421174 A1 FR 2421174A1
Authority
FR
France
Prior art keywords
new
preparation process
therapeutic applications
derivatives
carbostyrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7907863A
Other languages
English (en)
French (fr)
Other versions
FR2421174B1 (OSRAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of FR2421174A1 publication Critical patent/FR2421174A1/fr
Application granted granted Critical
Publication of FR2421174B1 publication Critical patent/FR2421174B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR7907863A 1978-03-30 1979-03-29 Nouveaux derives de carbostyrile, leur procede de preparation et leurs applications en therapeutique Granted FR2421174A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3778378A JPS54130587A (en) 1978-03-30 1978-03-30 Carbostyryl derivative

Publications (2)

Publication Number Publication Date
FR2421174A1 true FR2421174A1 (fr) 1979-10-26
FR2421174B1 FR2421174B1 (OSRAM) 1982-11-19

Family

ID=12507080

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7907863A Granted FR2421174A1 (fr) 1978-03-30 1979-03-29 Nouveaux derives de carbostyrile, leur procede de preparation et leurs applications en therapeutique

Country Status (21)

Country Link
US (2) US4734416A (OSRAM)
JP (1) JPS54130587A (OSRAM)
AT (1) AT376432B (OSRAM)
AU (1) AU515531B2 (OSRAM)
BE (1) BE875174A (OSRAM)
CA (1) CA1117110A (OSRAM)
CH (2) CH641455A5 (OSRAM)
DE (2) DE2953723C2 (OSRAM)
DK (1) DK158225C (OSRAM)
ES (4) ES479134A1 (OSRAM)
FI (1) FI70704C (OSRAM)
FR (1) FR2421174A1 (OSRAM)
GB (1) GB2017701B (OSRAM)
IT (1) IT1119284B (OSRAM)
MX (1) MX5862E (OSRAM)
NL (1) NL183189C (OSRAM)
NO (1) NO151321C (OSRAM)
PT (1) PT69422A (OSRAM)
SE (1) SE434945B (OSRAM)
SU (2) SU1140687A3 (OSRAM)
ZA (1) ZA791516B (OSRAM)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
DE3034237A1 (de) * 1979-09-18 1981-04-16 Otsuka Pharmaceutical Co. Ltd., Tokyo Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
JPS6129331A (ja) * 1985-03-13 1986-02-10 アラ−ガン・ハンフリ− 検眼装置
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
DK167187A (da) * 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
KR940000785B1 (ko) * 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
US4886809A (en) * 1986-07-31 1989-12-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof
JPH0696555B2 (ja) * 1986-07-31 1994-11-30 大塚製薬株式会社 カルボスチリル誘導体
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
EP1480953B2 (en) * 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20070179155A1 (en) * 2003-06-20 2007-08-02 Brian Smith N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
MXPA06004489A (es) 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
JP5546717B2 (ja) * 2003-12-16 2014-07-09 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾール結晶質形態を調製する方法
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
CA2555289A1 (en) * 2004-02-05 2005-08-25 Ben-Zion Dolitzky Process for preparing aripiprazole
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
CN101087760B (zh) * 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
CN101111481A (zh) * 2004-11-18 2008-01-23 斯索恩有限公司 制备结晶阿立哌唑的方法
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
EP1686126A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Salts of aripiprazole
CN101107242B (zh) * 2005-01-27 2011-08-10 桑多斯股份公司 阿立哌唑的盐
CA2600542A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1879569A2 (en) * 2005-04-22 2008-01-23 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
BRPI0608185A2 (pt) * 2005-12-22 2009-11-17 Teva Pharma processo para redução do tamanho de partìcula de aripiprazol
US20090054455A1 (en) * 2006-02-03 2009-02-26 Dr. Reddy's Laboratories Ltd. Aripiprazole co-crystals
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
EP1880714A1 (en) * 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) * 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US8039621B2 (en) * 2006-10-24 2011-10-18 Cambrex Charles City, Inc. Process for preparing anhydrous Aripirazole type I
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
BRPI0811844A2 (pt) * 2007-05-21 2014-11-18 Reviva Pharmaceuticals Inc Composto, e, método para tratar um paciente
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
ATE482691T1 (de) 2008-01-23 2010-10-15 Helm Ag Amorphes aripiprazol und verfahren zu seiner herstellung
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
NZ589764A (en) * 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
RU2555760C2 (ru) 2009-09-11 2015-07-10 Оцука Фармасьютикал Ко., Лтд. Терапевтический агент против хронической боли
WO2011030213A1 (en) 2009-09-14 2011-03-17 Jubilant Organosys Limited Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
DK2640391T3 (da) 2010-11-15 2016-02-15 Agenebio Inc Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse
EP3156056B1 (en) * 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US9951088B2 (en) * 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
PT2888234T (pt) * 2012-08-21 2018-02-22 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
KR20160139704A (ko) 2015-05-28 2016-12-07 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
MA42624A (fr) 2015-06-19 2021-04-28 Agenebio Inc Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
ES2963237A1 (es) * 2022-08-25 2024-03-25 Consejo Superior Investigacion Derivados de quinolina-2(1H)-ona para el tratamiento y prevención de enfermedades neurodegenerativas

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1561911A (OSRAM) * 1963-05-10 1969-04-04
FR2179715A1 (OSRAM) * 1972-04-13 1973-11-23 Otsuka Pharma Co Ltd
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
FR2344538A1 (fr) * 1976-03-17 1977-10-14 Otsuka Pharma Co Ltd Nouveaux derives de carbostyrile, utiles notamment comme b-bloquants cardio-selectifs, et leur procede de preparation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA801037A (en) * 1968-12-10 Regnier Gilbert Procede de preparation de nouveaux derives du piperazino-phenylethanol
GB1075156A (en) * 1963-08-27 1967-07-12 Luso Farmaco Inst Substituted piperazines
NL131192C (OSRAM) * 1965-06-16
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3703522A (en) * 1967-03-30 1972-11-21 Mcneilab Inc Carbostyril derivatives
US3706749A (en) * 1967-03-30 1972-12-19 Mcneilab Inc N-acyl carbostyrils
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
CH514611A (de) * 1968-07-05 1971-10-31 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des 2-Oxo-1,2-dihydro-chinolins
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
BE884459Q (fr) * 1971-05-14 1981-01-26 Boehringer Mannheim Gmbh Derives de la 4-(omega-(coumarine-7-yl-oxy)-alkyl)-piperazine et procede de preparation
DE2335432A1 (de) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung
US3910924A (en) * 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
US4256890A (en) * 1972-09-14 1981-03-17 Otsukapharmaceutical Co., Ltd. 3,4-Dihydrocarbostyril derivatives and process for producing the same
DE2354145A1 (de) * 1972-11-02 1974-05-16 Sandoz Ag Chinazolin-2(lh)-one und verfahren zu ihrer herstellung
DE2334009A1 (de) * 1973-07-04 1975-01-23 Boehringer Mannheim Gmbh Purin-derivate sowie verfahren zu ihrer herstellung
US4083853A (en) * 1973-09-08 1978-04-11 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US4026895A (en) * 1973-09-08 1977-05-31 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
GB1451900A (en) * 1973-10-30 1976-10-06 Sandoz Ltd Quinolin-2-1h-ones
JPS5089376A (OSRAM) * 1973-12-19 1975-07-17
US4032528A (en) * 1974-03-25 1977-06-28 Sandoz, Inc. 1,4-substituted-quinolin-2(1h)-ones as cns agents
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
DE2631317A1 (de) * 1975-07-23 1977-02-17 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
ES456325A1 (es) * 1976-02-27 1978-05-01 Sandoz Ag Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico.
US4210753A (en) * 1976-03-17 1980-07-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4110449A (en) * 1977-05-23 1978-08-29 E. R. Squibb & Sons, Inc. 2-substituted benzisothiazol-3-ones
US4166116A (en) * 1977-11-11 1979-08-28 Canadian Patents And Development Limited Pharmaceutical compositions containing piperazinyl acylhydroxamic acid derivatives to treat inflammation or anaphylactic allergy conditions
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1561911A (OSRAM) * 1963-05-10 1969-04-04
FR2179715A1 (OSRAM) * 1972-04-13 1973-11-23 Otsuka Pharma Co Ltd
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
FR2344538A1 (fr) * 1976-03-17 1977-10-14 Otsuka Pharma Co Ltd Nouveaux derives de carbostyrile, utiles notamment comme b-bloquants cardio-selectifs, et leur procede de preparation

Also Published As

Publication number Publication date
GB2017701B (en) 1983-03-16
FI70704C (fi) 1986-10-06
AU515531B2 (en) 1981-04-09
NL183189C (nl) 1988-08-16
AU4548079A (en) 1979-10-04
DK158225C (da) 1990-09-17
US4824840A (en) 1989-04-25
DK158225B (da) 1990-04-16
FI70704B (fi) 1986-06-26
DK128679A (da) 1979-10-26
DE2912105A1 (de) 1979-10-11
ES486990A1 (es) 1980-10-01
NO151321B (no) 1984-12-10
NL7902514A (nl) 1979-10-02
MX5862E (es) 1984-08-13
GB2017701A (en) 1979-10-10
AT376432B (de) 1984-11-26
CH641455A5 (de) 1984-02-29
PT69422A (en) 1979-04-01
ES486992A1 (es) 1980-10-01
BE875174A (fr) 1979-10-01
IT1119284B (it) 1986-03-10
SE7902794L (sv) 1979-10-01
JPS6223750B2 (OSRAM) 1987-05-25
NO151321C (no) 1985-03-20
SU1232144A3 (ru) 1986-05-15
SU1140687A3 (ru) 1985-02-15
DE2912105C2 (de) 1985-08-29
IT7967674A0 (it) 1979-03-30
FR2421174B1 (OSRAM) 1982-11-19
ES486991A1 (es) 1980-10-01
DE2953723C2 (de) 1989-01-12
NO791049L (no) 1979-10-02
JPS54130587A (en) 1979-10-09
US4734416A (en) 1988-03-29
SE434945B (sv) 1984-08-27
ATA235179A (de) 1984-04-15
ES479134A1 (es) 1980-06-16
FI791034A7 (fi) 1979-10-01
CH641350A5 (de) 1984-02-29
CA1117110A (en) 1982-01-26
ZA791516B (en) 1980-04-30

Similar Documents

Publication Publication Date Title
FR2421174A1 (fr) Nouveaux derives de carbostyrile, leur procede de preparation et leurs applications en therapeutique
FR2385722A1 (fr) Nouveaux derives de cephalosporine, leur procede de preparation et leur application en therapeutique
FR2387234A1 (fr) Derives de cephalosporine, leur procede de preparation et leurs applications en therapeutique
FR2378521A1 (fr) Derives du carbostyrile, utiles notamment comme stimulants des centres b- adrenorecepteurs, et leur procede de preparation
FR2415099A1 (fr) Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
FR2430419A1 (fr) Nouveaux derives de l'indole, leur preparation et leur application comme medicaments
FR2364219A1 (fr) Derives de thiazolidine, leur procede de preparation et leur application en therapeutique
FR2434154A1 (fr) Nouveaux derives d'imidazole, utiles notamment comme anticonvulsivants, et leur procede de preparation
FR2387980A1 (fr) Nouveaux 2-(2,2-diarylalkyl)-1-azabicyclo (2.2.2) octanes, utiles notamment comme antidiarrheiques, et leur procede de preparation
FR2405246A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et leurs applications en therapeutique
FR2428052A1 (fr) Nouveaux derives de 5-fluoro-(b-uridine ou 2'-desoxy-b-uridine), procede pour les preparer et agents carcinostatiques les renfermant
FR2354324A1 (fr) Nouveaux composes triazoliques, leur procede de preparation et leurs applications au traitement de plantes
FR2383165A1 (fr) Nouveaux derives d'acides phenoxy-a-phenoxy-alcanecarboxyliques, leur preparation et leur application comme herbicides
FR2380285A1 (fr) Nouveaux derives insatures d'acides 7-acylamido-3-cephem-4-carboxyliques, utiles notamment comme agents antibacteriens, et leur procede de preparation
FR2363563A1 (fr) Nouveaux derives de 1-acyloxymethyl-5-fluorouracile utiles notamment comme agents antitumoraux, et leur procede de preparation
FR2415636A1 (fr) Nouveaux derives de la guanidine, leur preparation et leur application comme medicaments
FR2436144A1 (fr) Nouveaux derives d'aurones, leur procede de preparation et leur utilisation comme produits pharmaceutiques
FR2384775A1 (fr) Derives de la morphine, leur procede de preparation et leur application comme medicament
FR2367742A1 (fr) Derives d'a-thio-alcanoiques, leur preparation et leur utilisation
FR2446829A1 (fr) Derives de polymethylene disubstitues en alpha, omega, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2357574A1 (fr) Nouveaux derives 16-acylthio de l'acide fusidique, utiles notamment comme antimicrobiens et leur procede de preparation
FR2358401A1 (fr) Nouveaux derives d'oxadiazine, leur procede de preparation et leur application comme insecticides
FR2378741A1 (fr) Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques
FR2421616A1 (fr) Nouveaux medicaments constitues de derives de l'acide o-aminobenzoique
FR2355831A1 (fr) Derives de benzazocine, leur procede de preparation et leur application therapeutique